LA JOLLA | Jotup

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

Retrieved on:

水曜日, 5月 8, 2024

Selection, Patient, Bank, Conference, SAN

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.

Key Points:

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.
To access a live webcast of the presentation, please visit the Events page in the Investors section of the Company’s website at www.turnstonebio.com .
Members of Turnstone’s senior management will also be available for one-on-one meetings during the conference.
Interested investors should contact their Bank of America Securities representative for further information.

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

Retrieved on:

火曜日, 5月 7, 2024

Tokyo Stock Exchange, Patent, MD, Patient, MPH, Code, Pharmaceutical industry

This new patent is expected to expire no earlier than September 2040.

Key Points:

This new patent is expected to expire no earlier than September 2040.
The allowed claims cover a formulation in the form of a tablet or capsule and cover a range of doses of MN-166 (ibudilast).
Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc., commented, "We are very pleased to receive the issue notification for this new patent and we believe it could increase the potential value of MN-166.
New extended-release formulations are more convenient for patients which may lead to improve compliance with the dosing schedule and to reduce undesirable side effect.”

Palomar Holdings, Inc. Reports First Quarter 2024 Results

Retrieved on:

木曜日, 5月 2, 2024

Investment, Conference, Growth, Eastern Time Zone, Insurance

LA JOLLA, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) reported net income of $26.4 million, or $1.04 per diluted share, for the first quarter of 2024 compared to net income of $17.3 million, or $0.68 per diluted share, for the first quarter of 2023.

Key Points:

LA JOLLA, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ:PLMR) (“Palomar” or “Company”) reported net income of $26.4 million, or $1.04 per diluted share, for the first quarter of 2024 compared to net income of $17.3 million, or $0.68 per diluted share, for the first quarter of 2023.
Adjusted net income(1) was $27.8 million, or $1.09 per diluted share, for the first quarter of 2024 as compared to $20.4 million, or $0.80 per diluted share, for the first quarter of 2023.
Mac Armstrong, Chairman and Chief Executive Officer, commented, “The strong results of our first quarter are a testament to Palomar's focus on profitable growth.
As previously announced, Palomar will host a conference call Friday May 3, 2024, to discuss its first quarter 2024 results at 11:00 a.m. (Eastern Time).

GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Retrieved on:

木曜日, 4月 25, 2024

Natural killer T cell, NKT, GRI, Doctor of Philosophy, LIVE

LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.

Key Points:

LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE!
with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.

Palomar Holdings, Inc. Announces First Quarter 2024 Financial Results Release Date and Conference Call

Retrieved on:

火曜日, 4月 23, 2024

Conference, Eastern Time Zone

LA JOLLA, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (the “Company”) today announced that it will release its first quarter 2024 results after the market close on Thursday, May 2, 2024, and will host a conference call at 11:00 a.m. (Eastern Time) the following day, Friday, May 3, 2024.

Key Points:

LA JOLLA, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (the “Company”) today announced that it will release its first quarter 2024 results after the market close on Thursday, May 2, 2024, and will host a conference call at 11:00 a.m. (Eastern Time) the following day, Friday, May 3, 2024.
The conference call can be accessed live by dialing 1-877-423-9813 or for international callers, 1-201-689-8573, and requesting to be joined to the Palomar First Quarter 2024 Earnings Conference Call.
A replay will be available starting at 4:00 p.m. (Eastern Time) on May 3, 2024, and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671.
The replay will be available until 11:59 p.m. (Eastern Time) on May 10, 2024.

Private Bancorp of America, Inc. Announces Strong Net Income and Earnings Per Share for First Quarter 2024

Retrieved on:

金曜日, 4月 19, 2024

LA JOLLA, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Private Bancorp of America, Inc. (OTCQX: PBAM), (“Company”) and CalPrivate Bank (“Bank”) announced unaudited financial results for the first fiscal quarter ended March 31, 2024. The Company reported net income of $7.9 million, or $1.36 per diluted share, for the first quarter of 2024, compared to $7.9 million, or $1.36, in the prior quarter, and $9.0 million, or $1.57, in the first quarter of 2023.

Key Points:

Net income for the first quarter of 2024 of $7.9 million, compared to $7.9 million in the prior quarter and $9.0 million in the first quarter of 2023.
The Company reported net income of $7.9 million, or $1.36 per diluted share, for the first quarter of 2024, compared to $7.9 million, or $1.36, in the prior quarter, and $9.0 million, or $1.57, in the first quarter of 2023.
The cost of total deposits was 2.61% for the first quarter of 2024 compared to 2.41% in the prior quarter.
Provision for income tax expense was $3.3 million for the first quarter of 2024, compared to $3.3 million for the prior quarter.

Turnstone Biologics Appoints William Waddill to its Board of Directors

Retrieved on:

火曜日, 4月 16, 2024

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.

Key Points:

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors.
The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.
“I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone,” said Sammy Farah, M.B.A., Ph.D., Turnstone’s President and Chief Executive Officer.
“Will is a highly accomplished biotechnology executive and Board member, and his impressive track record and deep operational and financial acumen make him a valuable addition to our Board.

GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent

Retrieved on:

火曜日, 4月 16, 2024

Natural killer T cell, IP, IPF, KIPO, GRI, Doctor of Philosophy, Idiopathic disease, NKT, RAR, Patent, Retinoic acid, Oxygen, Liver, Patient, Treatment, Movement, Idiopathic pulmonary fibrosis, Interim, Pharmaceutical industry

LA JOLLA, CA, April 16, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled, "Prevention and Treatment of Inflammatory Conditions."

Key Points:

The issued patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in the prevention and treatment of inflammatory conditions of the liver.
“We are pleased to add this Korea patent to our intellectual property portfolio covering our innovative pipeline of NKT cell modulators.
Each granted patent provides further validation and bolsters our confidence of our differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases.
For more information about the Company’s innovative pipeline of NKT cell regulators for the treatment of inflammatory, fibrotic and autoimmune diseases, visit gribio.com .

GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference

Retrieved on:

月曜日, 4月 8, 2024

GRI, Natural killer T cell, NKT, Conference

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.

Key Points:

LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ATS International Conference being held May 17-22, 2024 in San Diego, CA.
Details of the presentation are as follows:

Truepic, Revel.ai, and Nina Schick’s "Mirror of Reflection" Nominated for Best Use of AI Video in the 28th Annual Webby Awards

Retrieved on:

金曜日, 4月 5, 2024

Webby Awards, Coalition, The New York Times, International Academy, Perception, Internet, C2PA, Digital art, AI, Creativity, Generative, IADAS, Video

San Diego, CA, April 05, 2024 (GLOBE NEWSWIRE) -- Truepic , provider of secure content transparency infrastructure, announced that “ Mirror of Reflection ” has been nominated for Best Use of AI Video in the 28th Annual Webby Awards.

Key Points:

San Diego, CA, April 05, 2024 (GLOBE NEWSWIRE) -- Truepic , provider of secure content transparency infrastructure, announced that “ Mirror of Reflection ” has been nominated for Best Use of AI Video in the 28th Annual Webby Awards.
The video showcased how synthetic content can be ethically and interoperably labeled as computer-generated from the outset, enabling creators and AI companies to transparently indicate media origins.
Truepic securely implements the C2PA standard and Content Credentials across the technology stack for all forms of digital media.
“Nominees like Truepic are setting the standard for innovation and creativity on the internet,” said Nick Borenstein, General Manager of The Webby Awards.